DPP4 and type 2 diabetes mellitus: Besides, the observational study [15] showed that treatment with saxagliptin in older T2DM patients was not associated with an increased risk of fractures and DPP-4 inhibitor use was not associated with fracture risk compared to no anti-diabetes users and to non-insulin anti-diabetic drug (NIAD) users, respectively.